Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Mar;92(3):337–342. doi: 10.1111/j.1349-7006.2001.tb01100.x

Germline Mutation of Dihydropyrimidine Dehydrogenese Gene among a Japanese Population in Relation to Toxicity to 5‐Fluorouracil

Kensei Yamaguchi 1,2,✉, Yoshiko Aral 1, Yuzo Kanda 1, Kiwamu Akagi 2
PMCID: PMC5926718  PMID: 11267945

Abstract

5‐Fluorouracil (5FU) is most commonly used in chemotherapy for human malignancy. Over 80% of administered 5FU is metabolically degraded by dihydropyrimidine dehydrogenase (DPD), a primary and rate‐limiting enzyme in the 5FU metabolic pathway. A DPD‐deficient phenotype among cancer patients, which has posed a serious problem in 5FU‐based chemotherapy, was reported to be in part ascribed to germline mutations in dihydropyrimidine dehydrogenase (DPYD) gene. Therefore, we for the first tune examined the frequencies and types of germline mutations in the DPYD gene among a total of 107 Japanese cancer patients and healthy volunteers. Of 214 alleles examined among them, 181 alleles were of the same type, which was assigned as wild type; 21 alleles revealed a nucleotide substitution resulting in silent mutation; and the remaining 12 alleles showed five types of nucleotide deletion or substitutions resulting in one frameshift and four missense mutations. Three of them, A74G, 812delT and L572V, were novel mutations. None of the study subjects showed homozygous frameshift or missense mutated alleles. We also studied the association between toxic response to 5FU and heterozygous frame shift or missense mutation of the DPYD gene among eight cancer patients who had received 5FU‐based chemotherapy. These patients did not show any adverse effects higher than grade 3, suggesting that heterozygotes are not associated with increased toxicity to 5FU. Our results indicate that a very small percentage, about 0.2%, of the Japanese population seems to carry homozygous mutations in DPYD gene, mutations which possibly indicate genetically increased toxicity of 5FU‐based chemotherapy.

Keywords: therapy Dihydropyrimidine dehydrogenase gene, Germline mutation, 5FU‐based chemotherapy

Full Text

The Full Text of this article is available as a PDF (521.8 KB).

References

  • 1.Diasio , R. B. . and Harris , B. E.Clinical pharmacology of 5‐fluorouracil . Clin. Pharmacokinet , 16 , 215 – 237 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 2.Fleming , R. A. , Milano , G. , Thyss , A. , Etienne , M. C. , Renee , N. , Schneider , M. . and Bernard , F.Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononu‐clear cells and systemic clearance of fluorouracil in cancer patients . Cancer Res. , 52 , 2899 – 2902 ( 1992. ). [PubMed] [Google Scholar]
  • 3.Harris , B. E. , Song , R. , Soong , S. J. . and Diasio , R. B.Relationship between dihydropyrimidine dehydrogenase activity and plasma 5‐fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5‐fluorouracil by protracted continuous infusion . Cancer Res. , 50 , 197 – 201 ( 1990. ). [PubMed] [Google Scholar]
  • 4.Diasio , R. B.Sorivudine and 5‐fluorouracil; a clinically significant drug‐drug interaction due to inhibition of dihydropyrimidine dehydrogenase . Br. J. Clin. Pharmacol. , 46 , 1 – 4 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Meinsma , R. , Fernandez‐Salguero , P. , van Kuilenburg , A. B. P. , van Gennip , A. H. . and Gonzalez , F. J.Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea . DNA Cell Biol , 14 , 1 – 6 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 6.Vreken , P. , van Kuilenburg , A. B. P. , Meinsma , R. , de Abreu , R. A. . and van Gennip , A. H.Identification of a four‐base deletion (delTCAT296‐299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression . Hum. Genet. , 100 , 263 – 265 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 7.Vreken , P. , van Kuilenburg , A. B. P. , Meinsma , R. . and van Gennip , A. H.Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W . Hum. Genet. , 101 , 333 – 338 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 8.van Kuilenburg , A. B. P. , Vreken , P. , Riva , D. , Botteon , G. , Abeling , N. G. , Bakker , H. D. . and van Gennip , A. H.Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homo‐zygosity for the C29R mutation . J. Inherit. Metab. Dis. , 22 , 191 – 192 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 9.van Kuilenburg , A. B. P. , Vreken , P. , Abeling , N. G. , Bakker , H. D. , Meinsma , R. , van Lenthe , H. , de Abreu , R. A. , Smeitink , J. A. , Kayserili , H. , Apak , M. Y. , Christensen , E. , Holopainen , I. , Pulkki , K. , Riva , D. , Botteon , G. , Holme , E. , Tulinius , M. , Kleijer , W. J. , Beemer , F. A. , Duran , M. , Niezen‐Koning , K. E. , Smit , G. P. , Jakobs , C. , Smit , L. M. . and van Gennip , A. H.Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency . Hum. Genet. , 104 , 1 – 9 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 10.Wei , X. , McLeod , H. L. , McMurrough , J. , Gonzalez , F. J. . and Fernandez‐Salguero , P.Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5‐fluorou‐racil toxicity . J. Clin. Invest. , 98 , 610 – 615 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yamaguchi , K. , Sugano , K. , Fukayama , N. , Nakashima , Y. , Sao to me , K. , Yokoyama , T. , Yokota , T. . and Ohkura , H.Polymerase chain reaction‐based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms . Am. J. Gastroenterol. , 92 , 307 – 312 ( 1997. ). [PubMed] [Google Scholar]
  • 12.Wei , X. , Elizondo , G. , Sapone , A. , McLeod , H. L. , Raunio , H. , Fernandez‐Salguero , P. . and Gonzalez , F. J.Characterization of the human dihydropyrimidine dehydrogenase gene . Genomics , 51 , 391 – 400 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13.World Health Organization . “WHO Handbook for Reporting Results of Cancer Treatment ,” WHO Offset Publ. No.48 ( 1979. ). World Health Organization; , Geneva , Switzerland . [Google Scholar]
  • 14.Vreken , P. , van Kuilenburg , A. B. P. , Meinsma , R. , Beemer , F. A. , Duran , M. . and van Gennip , A. H.Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli. J. Inherit. Metab. Dis. , 21 , 276 – 279 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 15.McLeod , H. L. , Collie‐Duguid , E. S. , Vreken , P. , Johnson , M. R. , Wei , X. , Sapone , A. , Diasio , R. B. , Fernandez‐Salguero , P. , van Kuilenberg , A. B. P. , van Gennip , A. H. . and Gonzalez , F. J.Nomenclature for human DPYD alleles . Pharmacogenetics , 8 , 455 – 459 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 16.Ridge , S. A. , Sludden , J. , Brown , O. , Robertson , L. , Wei , X. , Sapone , A. , Fernandez‐Salguero , P. M. , Gonzalez , F. J. , Vreken , P. , van Kuilenburg , A. B. P. , van Gennip , A. H. . and McLeod , H. L.Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects . Br. J. Clin. Phar-macol , 46 , 151 – 156 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Fernandez‐Salguero , P. , Gonzalez , F. J. , Etienne , M. C. , Milano , G. . and Kimura , S.Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes . Biochem. Pharmacol. , 50 , 1015 – 1020 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 18.van Kuilenburg , A. B. P. , Vreken , P. , Beex , L. V. , Meinsma , R. , van Lenthe , H. , de Abreu , R. A. . and van Gennip , A. H.Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5‐fluorouracil related toxicity . Eur. J. Cancer , 13 , 2258 – 2264 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 19.Collie‐Duguid , E. S. , Etienne , M. C. , Milano , G. . and McLeod , H. L.Known variant DPYD alleles do not explain DPD deficiency in cancer patients . Pharmacogenetics , 10 , 217 – 223 ( 2000. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES